Background {#Sec1}
==========

There have been significant recent developments in the treatment of cancer with many new treatments demonstrating clinical evidence for improved survival and quality of life (QOL). Systemic anticancer therapy (SACT) now includes cytotoxic chemotherapy, endocrine or hormonal agents, targeted or biologic agents and immune checkpoint inhibitors. Non-chemotherapy treatments are often associated with simpler routes of administration, less but not negligible adverse effect profiles and the potential of profound and durable clinical responses. This has made the decision making process for commencing, continuing and ceasing SACT more complex and requires a careful consideration of key factors, specifically disease biology, patient and family expectations, and clinician biases.

Earle et al. \[[@CR1]\] have proposed several indicators for the assessment of quality of care near the end of life including the rate of chemotherapy administration; emergency department (ED) presentation, hospitalisation and intensive care unit (ICU) admission; and lack of or late referral to palliative care and hospice services. Over the last few decades, there is a trend towards more aggressive care with US registry studies finding an increase in patients receiving chemotherapy within 14 days of death; and increased rates of ED presentation, hospitalisation and ICU admission in the last month of life \[[@CR2]\]. Use of chemotherapy is associated with higher rates of cardiopulmonary resuscitation and mechanical ventilation, late hospice referral, death in ICU, and death in a non-preferred place \[[@CR3]\]. In the current context of immune checkpoint inhibitors, use near the end of life is associated with poorer performance status, lower hospice enrolment and higher rates of death in hospital \[[@CR4]\].

The rationale for SACT with palliative intent is primarily to improve or maintain quality of life. Despite this objective, the quality of life of patients as assessed by psychological and physical distress in the final week of life has been found to not improve in patients with moderate or poor performance status who received chemotherapy and in fact worsens in patients with good or excellent performance status who received chemotherapy \[[@CR5]\].

There is increasing evidence of the benefit of early involvement of palliative care for patients with cancer. The seminal randomised control study by Temel and colleagues \[[@CR6]\] demonstrated early palliative care consultation for patients with non small cell lung cancer (NSCLC) improved QOL, mood and depressive symptoms, and survival by more than two months. A secondary analysis of this study demonstrated that palliative care did not affect the number of chemotherapy regimens administered, but that chemotherapy near the end of life was reduced and hospice enrolment was higher \[[@CR7]\]. Both the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) have made recommendations in clinical practice guidelines for the concurrent use of SACT and early involvement of palliative care services for patients with advanced cancer \[[@CR8], [@CR9]\].

The first large scale report of mortality within 30 days of chemotherapy emanated from the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) conducted in the United Kingdom \[[@CR10]\]. The reported rate of mortality within 30 days of SACT was 2% and has become the historical benchmark. Subsequently, several centres have published data related to SACT within the last 30 days of life \[[@CR4], [@CR11]--[@CR28]\]. A selection of studies are summarised in Table [1](#Tab1){ref-type="table"} with focus on recent publications and the Australasian context. Comparisons between these studies are difficult for several reasons; studies differed with regard to: the included and excluded tumour types, treatment with curative and palliative intent, and treatment modality. Only three reports included immune checkpoint inhibitors. In addition, the studies reported different outcome measures most commonly the number of deaths within 30 days of treatment as a proportion of all patients who received treatment and, less commonly, as the number of deaths within 30 days of treatment as a proportion of all deaths. Table 1Summary of studies reporting systemic anticancer therapy near the end of lifeAuthorCountryPopulation studiedTreatment includedTreatment rate within last 30 days of lifeGilsch 2019 \[[@CR4]\]USADeaths of patients who received immune checkpoint inhibitorsI27%Ang 2018 \[[@CR11]\]New ZealandPatients who received SACTCT T I5.2%Burgers 2018 \[[@CR12]\]The NetherlandsPatients with stage III or IV lung cancer treated with SACTCT6.2% (within 30 days of first cycle of chemotherapy)GIlbar 2018 \[[@CR13]\]AustraliaPatients who received SACTCT T5.6%Hiramoto 2018 \[[@CR14]\]JapanDeaths of patients who received SACT with palliative intentCT16.7%Massa 2018 \[[@CR15]\]ItalyPatients with metastatic colorectal cancer who received SACTCT7.1% (last 14 days of life)Dasch 2017 \[[@CR16]\]GermanyInpatient deaths of patients with cancerCT38.3%Falchook 2017 \[[@CR17]\]USAPatients with metastatic lung, colorectal, breast, pancreas and prostate cancerCT10.1--14.1% (within the last 14 days of life)Kraut 2017 \[[@CR18]\]USADeaths of patients with cancerCT6--16%Wilson 2017 \[[@CR19]\]New ZealandPatients who received SACTCT2.2%Wallington 2016 \[[@CR20]\]UKPatients with lung cancer who received SACTCT T8%Patients with breast cancer who received SACTCTT2%Wein 2016 \[[@CR21]\]AustraliaDeaths of patients managed with palliative intentCT E T26%Khoja 2015 \[[@CR22]\]UKDeaths of patients who received SACTCT T I4%Pacetti 2015 \[[@CR23]\]ItalyDeaths of patients who received SACT with palliative intentCT24.3%Philip 2015 \[[@CR24]\]AustraliaMetastatic non small cell lung cancerCT1% (last 14 days of life)Andelkovic 2013 \[[@CR25]\]AustraliaPatients who received SACTCT T6.9%Zdenkowski 2013 \[[@CR26]\]AustraliaPatients who received SACT with palliative intentCT T12.2%Yoong 2012 \[[@CR27]\]AustraliaPatients who received SACTCT T3.4%Kao 2009 \[[@CR28]\]AustraliaDeaths of patients managed with palliative intentCT10%Mort 2008 \[[@CR10]\]UKPatients who received SACTCT2%Figure Legends: CT - chemotherapy, T - targeted therapy, I - immune checkpoint inhibitor, E - endocrine / hormonal therapy

Subsequent to NCEPOD, Christie Cancer Centre in the United Kingdom implemented its key recommendation to review all deaths within 30 days of SACT at a morbidity and mortality meeting and reassess progress through an audit process. Over a four year period, this practice did not reduce the rate of deaths within 30 days of SACT and had a minor but statistically insignificant reduction in the rate of treatment related deaths \[[@CR22]\]. In contrast, Wilson et al. reported two audits performed at Auckland Hospital six years apart \[[@CR19]\]. Mortality within 30 days of treatment with chemotherapy fell minimally with rates of 2.8% in 2009 and 2.2% in 2015. They proposed a series of clinical interventions that have informed this improvement implementation plan.

The aim of the study was to identify the rates of SACT within the last 30 days of life at the institution in order to compare with published benchmarks. We examined the use of the different types of SACT to observe any changing trends in practice given the development of new therapies, especially in the contemporary paradigm of immune checkpoint inhibitors. The audit also assessed other quality of care and aggressiveness of care parameters. Results from the initial audit informed the implementation of a service improvement plan which was then followed by a re-audit to assess any effect this improvement plan had on clinical practice. This study is novel in the emerging era of immune checkpoint inhibitors and contributes to our understanding of quality use of SACT, aggressiveness of care near the end of life and institution based interventions to improve the quality of patient care.

Methods {#Sec2}
=======

Data collection {#Sec3}
---------------

Data collected included age, gender, tumour type, performance status, intent of treatment, modality of systemic anticancer treatment, number of previous treatment lines, date of last treatment, date of death, date of referral to palliative care or hospice service, number of emergency department presentations, number of hospital admissions and number of intensive care unit admissions within the last 30 days of life. Systemic anticancer treatment was defined as cytotoxic chemotherapy, endocrine or hormonal treatments, targeted or biologic agents and immune checkpoint inhibitors.

Initial data collection {#Sec4}
-----------------------

A retrospective review was conducted of medical records for all patients managed at the Goulburn Valley Health oncology department who died between 1 January 2015 and 30 June 2018.

Improvement implementation plan {#Sec5}
-------------------------------

The following improvement implementation plan was enacted. Results were presented to the local cancer services educational meeting to an audience comprising medical oncologists, other medical staff, chemotherapy unit nurses, research nurses, specialist cancer support nurses and palliative care health professionals. This was conducted within a week of the conclusion of the audit period.Palliative care and community hospice services contact details were collated into a single resource and distributed to medical oncologists and other clinicians. This was conducted within a week of the conclusion of the audit period.Discussion at weekly departmental meeting of all patients being considered for anticancer therapy with performance status Eastern Cooperative Oncology Group (ECOG) score 3 or greater; or cases of concern for any other reasonAll clinicians to assess and record patient's performance status at commencement of anticancer treatment and at each subsequent outpatient clinic reviewReview of all cases of anticancer treatment within the last 30 days of life at monthly departmental mortality meetingCommitment to repeat audit in order to assess improvement

Repeat data collection {#Sec6}
----------------------

A retrospective review was repeated of medical records for all patients managed at the Goulburn Valley Health oncology department who died between 1 July 2018 and 31 December 2018.

Statistical analysis {#Sec7}
--------------------

The data was analysed using descriptive statistical techniques.

Results {#Sec8}
=======

Audit {#Sec9}
-----

### Patient characteristics {#Sec10}

In the initial audit period, there were 440 patients analysed. Patient characteristics are summarised in Table [2](#Tab2){ref-type="table"}. 60% were male. The average age was 72.5 years. Only 11% had a haematological diagnosis. Patients with performance status ECOG score 0 or 1 comprised 23%, ECOG 2 40% and ECOG 3 or 4 38% of the total. The most common diagnoses were lung (87 patients), colorectal (62 patients), breast (42 patients), prostate (40 patients) and pancreas (34 patients) (Table [6](#Tab6){ref-type="table"}). Table 2Characteristics of patients in the the audit periodAll PatientsTreatment within last 30 daysNo treatment within last 30 daysNumberPercentNumberPercentNumberPercent44012027%32073%Sex Male26360%6756%19661% Female17740%5344%12439%Discipline Oncology39289%10326%28974% Hematology4811%1735%3165% Average age (years)72.57173.3Performance status ECOG 0 or 19923%3428%6520% ECOG 217540%4437%13141% ECOG 3 or 416638%4235%12439%Line of treatment Never treated8920%8928% First line17039%5949%11135% Second line10825%3630%7223% Third line or greater7317%2521%4815%

### Anticancer treatment {#Sec11}

Details of treatments are described in Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}. 20% of patients had not received any anticancer therapy and managed solely with best supportive care. 39% had received one line of treatment, 25% had received two lines of treatment and 17% had received three or more lines of treatment. 120 patients of the total 440 deaths (27%) had received anticancer treatment within the last 30 days of life. Table 3Treatment and aggressiveness of care in the audit periodAll PatientsTreatment within last 30 daysNo treatment within last 30 daysNumberPercentNumberPercentNumberPercentLast treatment type Chemotherapy2436627%17773% Targeted/biologic472043%2757% Endocrine/hormonal532547%2853% Immunotherapy301447%1653%Treatment intent Curative194%54%144% Palliative42196%11596%30696%Parameters for aggressiveness of care Palliative care referral27265%6758%20567% Palliative care referral beyond last 30 days17842%3228%14648% More than one emergency presentations4310%2118%227% More than one hospitalisation4912%2017%299% Hospitalisation 14 or more days6014%1311%4715% ICU admission164%76%93%

66 of 243 patients (27%) whose last anticancer treatment was chemotherapy received chemotherapy within the last 30 days of life. This indicator was higher with the other treatment modalities: 43% in targeted / biologic agents, 47% in endocrine / hormonal agents and 47% in immune checkpoint inhibitors. Of the total number of patients who received chemotherapy, treatment within the last 30 days of life represented 8% of patients.

### Aggressiveness of care {#Sec12}

421 (96%) were treated with palliative intent. Of these, 65% of patients had a referral to palliative care or community hospice services. Referral was often late with 58% of referrals made within the last 30 days of life. Receiving treatment within the last 30 days of life when compared with not, was associated with higher rates of late palliative care referral (72% compared with 52%), more than one ED presentation (18% vs 7%), more than one hospital admission (17% vs 9%) and ICU admission (6% vs 3%).

Re-audit {#Sec13}
--------

### Patient characteristics {#Sec14}

The re-audit period comprised 75 patients as summarised in Table [4](#Tab4){ref-type="table"}. 53% were male. The average age was 70 years. Only 13% had a haematological diagnosis. Patients with performance status ECOG score 0 or 1 comprised 40%, ECOG 2 39% and ECOG 3 or 4 21% of the total. The most common diagnoses were colorectal (14 patients), lung (10 patients), prostate (7 patients), breast (6 patients), upper GI (5 patients) and melanoma (5 patients) (Table [6](#Tab6){ref-type="table"}). Table 4Characteristics of patients in the the re-audit periodAll PatientsTreatment within last 30 daysNo treatment within last 30 daysNumberPercentNumberPercentNumberPercent751925%5675%Sex Male4053%1053%3054% Female3547%947%2646%Discipline Oncology6587%1929%4671% Hematology1013%00%10100% Average age (years)70.166.971.1Performance status ECOG 0 or 13040%421%2646% ECOG 22939%737%2239% ECOG 3 or 41621%842%814%Line of treatment Never treated68%611% First line2533%316%2239% Second line2533%1053%1527% Third line or greater1925%632%1323%

### Anticancer treatment {#Sec15}

The treatments and aggressiveness of care in the re-audit period is summarised in Table [4](#Tab4){ref-type="table"} and Table [5](#Tab5){ref-type="table"}. 8% of patients had not received any anticancer therapy whereas 33% had received one line of treatment, 33% had received two lines of treatment and 25% had received three or more lines of treatment. 19 patients of the total 75 deaths (25%) had received anticancer treatment within the last 30 days of life. 6 of 47 (13%) patients whose last anticancer treatment was chemotherapy received a dose within the last 30 days of life. This was substantially lower compared with the audit period. This indicator also reduced with respect to endocrine/hormonal treatments (33%) and remained stable with respect to targeted/biologics (42%). There was a substantial increase with regard to immune checkpoint inhibitors. 89% of patients, whose last treatment was an immune checkpoint inhibitor, received a dose within the last 30 days of life. This is demonstrated in Fig. [1](#Fig1){ref-type="fig"}. Of the total number of patients who received chemotherapy, treatment within the last 30 days of life represented 2% of patients. Table 5Treatment and aggressiveness of care in the re-audit periodAll PatientsTreatment within last 30 daysNo treatment within last 30 daysNumberPercentNumberPercentNumberPercentLast treatment type Chemotheratpy47613%4187% Targeted/biologic12542%758% Endocrine/hormonal6233%467% Immunotherapy9889%111%Treatment intent Curative68%15%59% Palliative6992%1895%5191%Parameters for aggressiveness of care Palliative care referral5580%1583%4078% Palliative care referral beyond last 30 days4261%1267%3059% More than one emergency presentations69%211%48% More than one hospitalisation710%317%48% Hospitalisation 14 or more days1522%422%1122% ICU admission46%16%36% Fig. 1Comparison of rates of treatment between audit and re-audit period by treatment type

### Aggressiveness of care {#Sec16}

92% of patients were treated with palliative intent. The rate of palliative care or hospice service referral was significantly improved to 80%. Late referrals were less frequent with 39% of referrals occurring in the last 30 days of life. Treatment within the last 30 days of life was again associated with more patients having more than one hospital admission (17% vs 8%). The rate of more than one ED presentation (11% vs 8%), ICU admission (6% vs 6%) and hospital admission greater than 14 days was similar (22% vs 22%).

Discussion {#Sec17}
==========

Clinical audit is an essential part of clinical governance used to assess current performance and an important tool for practice improvement \[[@CR29]\]. Audits have been found to have a small but potential important impact on professional practice \[[@CR30]\]. This study reviewed 440 patient deaths and examined for patterns in SACT and other parameters of aggressiveness of care. A multifaceted quality improvement implementation plan was implemented and a re-audit of a further 75 patient deaths was conducted to assess the effect of this intervention. Components of the intervention have previously been proposed by other authors \[[@CR10], [@CR19]\]. The intervention was simple and can easily be replicated at other centres. The mechanism of the intervention is multifaceted. The initial education session raises awareness of this issue and reports on current performance. Regular reviews of all cases at morbidity and mortality meetings maintains awareness and allows repeated feedback to clinicians. Mandated repeat assessment of performance status and discussion of borderline cases at treatment commencement provide a decision point which can break up treatment inertia. Finally, simplifying referral processes to palliative care and hospice services supports patients, families and clinicians in symptom management, maximising the use of SACT and transitioning to the end of life period.

Overall, the patient population was as expected of a regional cancer centre with a predominance of solid tumour types representing the common cancer diagnoses and a broad spread of patient performance status. The rate of SACT within the last 30 days of life was 27% in the initial audit period and remained stable at 25% during the re-audit period. Review of the literature, as summarised in Table [1](#Tab1){ref-type="table"}, did not find a published report to consider all treatment modalities, namely cytotoxic chemotherapy, endocrine and hormonal agents, targeted and biologic agents and immunotherapy. When comparing this figure to other published reports, it is important to note that this statistic is the number of deaths within the last 30 days of life as a proportion of all deaths of patients managed at the Goulburn Valley Health oncology department. A similar statistic in the Australian context was reported by Wein et al. at a rate of 26% but only included patients treated with palliative intent and did not include immunotherapy \[[@CR21]\]. Other authors have reported treatment rates as a proportion of patient deaths between 4 and 38% \[[@CR14], [@CR16], [@CR18], [@CR21]--[@CR23], [@CR28]\].

The more commonly reported statistic is the number of deaths within 30 days of SACT as a proportion of all patients who received SACT. We calculated a comparable statistic where the number of deaths of patients who received chemotherapy within the last 30 days of life expressed as a percentage of all patients who received chemotherapy was initially 8% and fell substantially to 2% during the re-audit period. This compares well with reports from other centres and is in fact the lowest reported rate in Australasian region \[[@CR11], [@CR13], [@CR19], [@CR24]--[@CR27]\].

This study is one of only a few to include immunotherapy in assessing mortality within 30 days of treatment. A recent study from New Zealand reported a rate of SACT within the last 30 days of life of 5.2% \[[@CR11]\]. This included chemotherapy, targeted therapies and immunotherapy, but excluded endocrine / hormonal treatments. It should be noted that this was measured as a proportion of all patients who received SACT. Gilsch et al. conducted a retrospective review of 157 deceased patients treated with immune checkpoint inhibitors and reported that 27% received a dose within the last 30 days of life \[[@CR4]\]. This is substantially lower than our rates of 47% in the audit period and 89% in the re-audit period.

SACT within the last 30 days of life with cytotoxic chemotherapy occurred in 27% and in higher proportions in non-chemotherapy treatments, specifically endocrine and hormonal agents 47%, targeted and biologic agents 43%, and immune checkpoint inhibitors 47%. Interestingly, this rate rose to 89% during the re-audit period with regard to immune checkpoint inhibitors whereas rates for endocrine / hormonal agents and targeted/biologic agents remained stable and the rate of chemotherapy use near the end of life fell to 13% (Fig. [1](#Fig1){ref-type="fig"}). This should be interpreted with caution due to the small patient numbers and short re-audit period. Possible explanations for these trends include the increasing availability and number of indications for immune checkpoint inhibitors over the recent period. Furthermore, non-chemotherapy treatments have a more tolerable side effect profile and may be more accepted by patients and clinicians when treatment decisions are being made. These factors may contribute to a shift in treatment modalities from chemotherapy towards immune checkpoint inhibitors. Also, the composition of tumour types between the audit and re-audit periods was different (Table [6](#Tab6){ref-type="table"}) and may affect the types of treatments used. Table 6Top 10 most common tumour types in audit and re-audit periodsAuditRe-auditTumour typeNumberPercentTumour typeNumberPercentLung8720Colorectal1419Colorectal6214Lung1013Breast4210Prostate79Prostate409Breast68Pancreas348Upper GI57Upper GI297Melanoma57Urothelial184Lymphoma45Gynaecological153Cholangiocarcinoma45Lymphoma143Head and neck45Melanoma102Gynaecological34

When the other parameters of aggressiveness of care are examined, the re-audit period was notable for an increase in palliative care referrals (78% vs 65%) and decrease in late palliative care referrals (41% vs 58%). This did not seem to affect the other indicators of aggressiveness of care. Similar rates of more than one ED presentation, more than one hospitalisation and ICU admission were seen in the audit and re-audit period. The rate of hospital admission for more than 14 days rose from 14 to 22% after the intervention. This is demonstrated in Fig. [2](#Fig2){ref-type="fig"}. The association of treatment within the last 30 days of life and increased rates of more than one hospitalised was observed before and after the intervention but was not maintained with regard to more than one ED presentation or ICU admission. Fig. 2Comparison of indicators of aggressiveness of care between the audit and re-audit periods

Limitations to this project should be noted. Data has been collected in a retrospective manner. Data was collected from patient medical records which relies on complete and accurate documentation. Furthermore, patients in regional areas often have shared care between different centres and therefore a number of outcome events may not be captured in this data collection. The re-audit period was relatively shorter than the initial audit period and the observed trends in practice may attenuate over a longer period of time. The re-audit period was considered to have started immediately after the audit period which resulted in a short period of time before clinicians were fully exposed to the improvement implementation plan. The educational meeting and palliative care contacts were enacted within a week of the conclusion of the audit period. However, there may have been a learning curve period as clinicians gained repeated exposure and feedback from the regular case and mortality meetings. Nonetheless, these factors would likely have contributed to an underestimation of the effect of the improvement implementation plan.

Conclusion {#Sec18}
==========

This study provides a contemporaneous benchmark for SACT and other parameters of aggressiveness of care within the last 30 days of life in an Australian regional setting. Importantly, the changing treatment paradigm with the increasing use of immune checkpoint inhibitors and other targeted agents is considered. It also establishes the components of a quality improvement implementation plan and demonstrates its impact on use of SACT and palliative care referral practices. Further research is required into the factors which affect the treatment decision making process in order to ensure quality of care.
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